Somaiya Mayur Ian's Form 4 filing
NewAmsterdam Pharma Co N.V.NAMS · filed Jan 29, 2025
- Accession no.
- 0000950170-25-010594
- Filed
- Jan 29, 2025
- Trade date
- Jan 27-28, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 2 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Somaiya Mayur IanCIK 0001760303 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 27, 2025 | Ordinary Shares | MOption exerciseAcquired | +46,983 | $9.26 | +$435,062.58 | 84,983 | Direct | |
| Jan 27, 2025 | Ordinary Shares | SSaleDisposed | −33,679 | –F2 | – | 51,304 | Direct | |
| Jan 27, 2025 | Ordinary Shares | SSaleDisposed | −13,304 | –F3 | – | 38,000 | Direct | |
| Jan 28, 2025 | Ordinary Shares | MOption exerciseAcquired | +14,900 | $9.26 | +$137,974 | 52,900 | Direct | |
| Jan 28, 2025 | Ordinary Shares | SSaleDisposed | −11,495 | –F4 | – | 41,405 | Direct | |
| Jan 28, 2025 | Ordinary Shares | SSaleDisposed | −3,405 | –F5 | – | 38,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 27, 2025 | Ordinary Shares | MOption exerciseDisposed | −46,983 | $0.00 | $0 | 777,714 | Direct | |
| Jan 28, 2025 | Ordinary Shares | MOption exerciseDisposed | −14,900 | $0.00 | $0 | 762,814 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
These shares were sold in multiple transactions at prices ranging from $22.38 per share to $23.37 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
Referenced by the price of 1 transaction in Table I.
- F3
These shares were sold in multiple transactions at prices ranging from $23.38 per share to $23.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
Referenced by the price of 1 transaction in Table I.
- F4
These shares were sold in multiple transactions at prices ranging from $20.93 per share to $21.92 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
Referenced by the price of 1 transaction in Table I.
- F5
These shares were sold in multiple transactions at prices ranging from $21.93 per share to $22.41 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
Referenced by the price of 1 transaction in Table I.